Trial
NCT02993783
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Millennium Pharmaceuticals, Inc.
Collaborators
—
Condition
Allogeneic Hematopoietic Stem Cell Transplantation
Intervention
Vedolizumab
Why stopped
Lack of efficacy of the drug; no safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-24